Published in Haematologica on September 30, 2010
Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia (2013) 3.08
IMWG consensus on risk stratification in multiple myeloma. Leukemia (2013) 2.28
Molecular pathogenesis of multiple myeloma and its premalignant precursor. J Clin Invest (2012) 2.24
Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120). Blood (2013) 1.98
NEK2 induces drug resistance mainly through activation of efflux drug pumps and is associated with poor prognosis in myeloma and other cancers. Cancer Cell (2013) 1.67
Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma. Leukemia (2014) 1.56
Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma. Blood (2012) 1.56
Molecular pathogenesis of multiple myeloma: basic and clinical updates. Int J Hematol (2013) 1.04
SULFs in human neoplasia: implication as progression and prognosis factors. J Transl Med (2011) 1.02
Genes with a spike expression are clustered in chromosome (sub)bands and spike (sub)bands have a powerful prognostic value in patients with multiple myeloma. Haematologica (2011) 1.01
Cancer testis antigens in newly diagnosed and relapse multiple myeloma: prognostic markers and potential targets for immunotherapy. Haematologica (2011) 1.00
Many multiple myelomas: making more of the molecular mayhem. Hematology Am Soc Hematol Educ Program (2011) 1.00
Identification of an ABCB1 (P-glycoprotein)-positive carfilzomib-resistant myeloma subpopulation by the pluripotent stem cell fluorescent dye CDy1. Am J Hematol (2013) 0.96
Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood (2011) 0.95
Krüppel-like factor 4 blocks tumor cell proliferation and promotes drug resistance in multiple myeloma. Haematologica (2013) 0.95
Identification of pluripotent and adult stem cell genes unrelated to cell cycle and associated with poor prognosis in multiple myeloma. PLoS One (2012) 0.93
Clinical value of molecular subtyping multiple myeloma using gene expression profiling. Leukemia (2015) 0.90
Inhibition of DEPDC1A, a bad prognostic marker in multiple myeloma, delays growth and induces mature plasma cell markers in malignant plasma cells. PLoS One (2013) 0.89
Expression of L-type amino acid transporter 1 (LAT1) as a prognostic and therapeutic indicator in multiple myeloma. Cancer Sci (2014) 0.88
DNA repair pathways in human multiple myeloma: role in oncogenesis and potential targets for treatment. Cell Cycle (2013) 0.86
The use of molecular-based risk stratification and pharmacogenomics for outcome prediction and personalized therapeutic management of multiple myeloma. Int J Hematol (2011) 0.86
Prediction of high- and low-risk multiple myeloma based on gene expression and the International Staging System. Blood (2015) 0.86
Preclinical efficacy of sepantronium bromide (YM155) in multiple myeloma is conferred by down regulation of Mcl-1. Oncotarget (2014) 0.84
Implications of heterogeneity in multiple myeloma. Biomed Res Int (2014) 0.82
Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120). Haematologica (2015) 0.82
A DNA repair pathway score predicts survival in human multiple myeloma: the potential for therapeutic strategy. Oncotarget (2014) 0.82
Translating a gene expression signature for multiple myeloma prognosis into a robust high-throughput assay for clinical use. BMC Med Genomics (2014) 0.81
The role of DNA damage and repair in decitabine-mediated apoptosis in multiple myeloma. Oncotarget (2014) 0.81
PTTG1 expression is associated with hyperproliferative disease and poor prognosis in multiple myeloma. J Hematol Oncol (2015) 0.79
Clinical implication of centrosome amplification and expression of centrosomal functional genes in multiple myeloma. J Transl Med (2013) 0.78
Inhibiting the anaphase promoting complex/cyclosome induces a metaphase arrest and cell death in multiple myeloma cells. Oncotarget (2016) 0.78
miRNAs in multiple myeloma - a survival relevant complex regulator of gene expression. Oncotarget (2015) 0.78
Profound impact of sample processing delay on gene expression of multiple myeloma plasma cells. BMC Med Genomics (2015) 0.78
The glycome of normal and malignant plasma cells. PLoS One (2013) 0.77
RECQ helicases are deregulated in hematological malignancies in association with a prognostic value. Biomark Res (2016) 0.76
Chetomin, targeting HIF-1α/p300 complex, exhibits antitumour activity in multiple myeloma. Br J Cancer (2016) 0.76
Search for rare protein altering variants influencing susceptibility to multiple myeloma. Oncotarget (2017) 0.75
In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma. Oncotarget (2015) 0.75
Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma without Cryopreservation. Bone Marrow Res (2012) 0.75
Gene signature combinations improve prognostic stratification of multiple myeloma patients. Leukemia (2015) 0.75
High levels of circulating CD34+ cells at autologous stem cell collection are associated with favourable prognosis in multiple myeloma. Br J Cancer (2011) 0.75
DNA methylation score is predictive of myeloma cell sensitivity to 5-azacitidine. Br J Haematol (2013) 0.75
Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control. Blood Cancer J (2017) 0.75
Gene Expression Profiles in Myeloma: Ready for the Real World? Clin Cancer Res (2016) 0.75
Longitudinal fluorescence in situ hybridization reveals cytogenetic evolution in myeloma relapsing after autologous transplantation. Haematologica (2017) 0.75
RECQ1 helicase is involved in replication stress survival and drug resistance in multiple myeloma. Leukemia (2017) 0.75
Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci U S A (1999) 14.16
International staging system for multiple myeloma. J Clin Oncol (2005) 11.29
Multiple myeloma. N Engl J Med (2004) 10.81
A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer (1975) 10.04
The molecular classification of multiple myeloma. Blood (2006) 8.77
A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood (2006) 7.63
Recycling the cell cycle: cyclins revisited. Cell (2004) 6.04
Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. Blood (2007) 5.55
Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res (2004) 4.54
Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood (2005) 4.04
Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol (2005) 3.93
Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood (1993) 2.98
Generation of polyclonal plasmablasts from peripheral blood B cells: a normal counterpart of malignant plasmablasts. Blood (2002) 2.48
Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma. Blood (1994) 2.10
The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature. Blood (2005) 1.96
Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies. Blood (2005) 1.71
Ploidy, as detected by fluorescence in situ hybridization, defines different subgroups in multiple myeloma. Leukemia (2005) 1.49
Delineation of distinct subgroups of multiple myeloma and a model for clonal evolution based on interphase cytogenetics. Genes Chromosomes Cancer (2005) 1.39
Agonist anti-gp130 transducer monoclonal antibodies are human myeloma cell survival and growth factors. Leukemia (2000) 1.35
Critical roles for immunoglobulin translocations and cyclin D dysregulation in multiple myeloma. Immunol Rev (2003) 1.29
A gp130 interleukin-6 transducer-dependent SCID model of human multiple myeloma. Blood (1998) 1.27
The growth fraction of human myeloma cells. Blood (1981) 1.24
Induction of angiogenesis by normal and malignant plasma cells. Blood (2009) 1.22
Value of beta 2-microglobulin level and plasma cell labeling indices as prognostic factors in patients with newly diagnosed myeloma. Blood (1988) 1.21
Staging and kinetics of multiple myeloma. Semin Oncol (1986) 1.19
Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma. Blood (2009) 1.16
Ploidy and proliferative characteristics in monoclonal gammopathies. Blood (1982) 1.15
Low plasma cell 3(H) thymidine incorporation in monoclonal gammopathy of undetermined significance (MGUS), smouldering myeloma and remission phase myeloma: a reliable indicator of patients not requiring therapy. Br J Haematol (1984) 1.12
Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis. Oncogene (2009) 1.10
Measurement of apoptosis and proliferation of bone marrow plasma cells in patients with plasma cell proliferative disorders. Br J Haematol (1999) 1.05
Immunofluorescence labeling indices in myeloma and related monoclonal gammopathies. Mayo Clin Proc (1987) 1.00
Inhibitors of kinesin motor proteins--research and clinical progress. Curr Opin Drug Discov Devel (2005) 0.99
A high bone marrow plasma cell labeling index in stable plateau-phase multiple myeloma is a marker for early disease progression and death. Blood (2001) 0.93
Ki-67 proliferation index: correlation with prognostic parameters and outcome in multiple myeloma. Am J Clin Oncol (2004) 0.92
A new staging system for multiple myeloma based on the number of S-phase plasma cells. Blood (1995) 0.91
Determination of the plasma cell labelling index with bromodeoxyuridine in a double fluorescence technique. Br J Haematol (1986) 0.89
Plasma cell proliferation in monoclonal gammopathies: measurement using BU-1 antibody in flow cytometry and microscopy: comparison with serum thymidine kinase. J Clin Pathol (1995) 0.78
A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med (2003) 16.11
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med (2005) 15.30
Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med (2008) 13.02
International staging system for multiple myeloma. J Clin Oncol (2005) 11.29
Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature (2012) 10.99
The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med (2003) 10.67
The molecular classification of multiple myeloma. Blood (2006) 8.77
Medulloblastoma comprises four distinct molecular variants. J Clin Oncol (2010) 8.06
A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood (2006) 7.63
Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell (2007) 7.10
The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol (2010) 7.08
Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell (2012) 6.71
Reprogramming transcription by distinct classes of enhancers functionally defined by eRNA. Nature (2011) 6.10
Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood (2002) 5.47
High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell (2006) 5.01
CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. J Clin Oncol (2004) 5.01
XBP1 controls diverse cell type- and condition-specific transcriptional regulatory networks. Mol Cell (2007) 4.93
Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med (2010) 4.76
Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res (2004) 4.54
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol (2013) 4.30
Comparative characteristics of mesenchymal stem cells from human bone marrow, adipose tissue, and umbilical cord blood. Exp Hematol (2005) 4.27
Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood (2005) 4.04
DNA ligase IV-dependent NHEJ of deprotected mammalian telomeres in G1 and G2. Curr Biol (2002) 3.95
Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial. J Clin Oncol (2012) 3.93
The genomic and transcriptomic landscape of a HeLa cell line. G3 (Bethesda) (2013) 3.82
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood (2007) 3.66
Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood (2006) 3.64
A meta-analysis of human embryonic stem cells transcriptome integrated into a web-based expression atlas. Stem Cells (2007) 3.62
Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol (2006) 3.60
Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br J Haematol (2007) 3.41
Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood (2006) 3.39
FSTL5 is a marker of poor prognosis in non-WNT/non-SHH medulloblastoma. J Clin Oncol (2011) 3.33
Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities. Blood (2008) 3.22
V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood (2002) 3.17
Multiple myeloma: clinical review and diagnostic imaging. Radiology (2004) 3.12
Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma. Cancer Cell (2011) 3.11
Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin Cancer Res (2003) 3.10
F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood (2009) 3.02
Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci. J Clin Oncol (2009) 3.01
High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis. Blood (2007) 2.91
Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood (2006) 2.91
BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood (2003) 2.82
The eEF2 kinase confers resistance to nutrient deprivation by blocking translation elongation. Cell (2013) 2.74
p16INK4a immunohistochemistry improves interobserver agreement in the diagnosis of cervical intraepithelial neoplasia. Am J Surg Pathol (2002) 2.73
Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial. Lancet Oncol (2010) 2.66
Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers. Gastroenterology (2008) 2.64
Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2. Br J Haematol (2008) 2.64
Topoisomerase I suppresses genomic instability by preventing interference between replication and transcription. Nat Cell Biol (2009) 2.60
Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol (2010) 2.58
Prospective evaluation of operating characteristics of prostate cancer detection biomarkers. J Urol (2010) 2.54
Generation of polyclonal plasmablasts from peripheral blood B cells: a normal counterpart of malignant plasmablasts. Blood (2002) 2.48
Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J Clin Oncol (2008) 2.45
Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients. Blood (2010) 2.42
Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica (2006) 2.40
Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. Blood (2011) 2.37
Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol (2009) 2.32
Targeting the BRAF V600E mutation in multiple myeloma. Cancer Discov (2013) 2.32
Long-term outcome results of the first tandem autotransplant trial for multiple myeloma. Br J Haematol (2006) 2.32
Molecular staging of intracranial ependymoma in children and adults. J Clin Oncol (2010) 2.27
Strong correlation between serum aspergillus galactomannan index and outcome of aspergillosis in patients with hematological cancer: clinical and research implications. Clin Infect Dis (2008) 2.26
Heparanase enhances syndecan-1 shedding: a novel mechanism for stimulation of tumor growth and metastasis. J Biol Chem (2007) 2.25
Pathogenesis of DNA repair-deficient cancers: a statistical meta-analysis of putative Real Common Target genes. Oncogene (2003) 2.21
Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia. J Clin Oncol (2006) 2.15
Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma. Leuk Lymphoma (2012) 2.14
CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res (2008) 2.13
Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. J Clin Oncol (2007) 2.13